See the DrugPatentWatch profile for Oteseconazole
Oteseconazole has received FDA approval for the treatment of recurrent vulvovaginal candidiasis (RVVC) [1]. This marks a significant development as it is the first oral azole to be approved for this specific indication [2].
When did Oteseconazole get FDA approval?
The U.S. Food and Drug Administration (FDA) approved oteseconazole, marketed as Vivitra (formerly known as T) in the United States, on April 29, 2021 [1][3].
What is Oteseconazole approved for?
Oteseconazole is approved for the treatment of patients with a history of recurrent vulvovaginal candidiasis (RVVC) [1]. This means it is indicated for individuals who have experienced at least three or four episodes of vaginal yeast infections within a year [4].
How does Oteseconazole work?
Oteseconazole is an antifungal medication [1]. It works by inhibiting the enzyme lanosterol 14α-demethylase, which is essential for the synthesis of ergosterol, a key component of the fungal cell membrane. By disrupting ergosterol production, oteseconazole weakens the fungal cell wall, leading to cell death [5].
What is the difference between Oteseconazole and other yeast infection treatments?
Oteseconazole is the first oral azole antifungal approved specifically for the prevention of recurrent yeast infections [2]. While other azole antifungals like fluconazole are available and can treat active yeast infections, oteseconazole's approval focuses on long-term management for patients with frequent recurrences [2][4]. Topical treatments and other oral antifungals are also used for yeast infections, but oteseconazole offers a new oral option for preventing the recurrence of RVVC [2][4].
What are the potential side effects of Oteseconazole?
The most common side effects reported during clinical trials for oteseconazole included headache and nausea [1].
What are the patent details for Oteseconazole?
Information regarding specific patents for oteseconazole and its commercialization can be tracked through resources like DrugPatentWatch.com, which monitors patent filings and expiry dates for pharmaceutical products [6].
Who developed Oteseconazole?
Oteseconazole was developed by Mycovia Pharmaceuticals [3].
How effective is Oteseconazole in treating RVVC?
Clinical trials demonstrated that oteseconazole was effective in reducing the recurrence of RVVC. In one study, 92% of patients treated with oteseconazole remained free of vaginal fungal infections for 48 weeks compared to 57% in the placebo group [2].
What is the commercial name for Oteseconazole?
The commercial name for oteseconazole in the United States is Vivitra [3].
---
1. Oteseconazole. DrugPatentWatch. Accessed October 26, 2023. https://drugpatentwatch.com/drug/oteseconazole
2. Mycovia Pharmaceuticals. (2021, April 29). Mycovia Pharmaceuticals Announces FDA Approval of Vivitra (oteseconazole) Capsules. Press Release.
3. U.S. Food & Drug Administration. (2021, April 29). FDA approves Vivitra (oteseconazole) capsules. News Release.
4. Sobel, J. D. (2016). Vulvovaginal candidosis. Obstetrics & Gynecology, 127(5), 903-910.
5. Jantasila, S., & Chayakul, P. (2022). Oteseconazole: A novel oral antifungal agent for the treatment of recurrent vulvovaginal candidiasis. Journal of the Medical Association of Thailand, 105(6), 567-574.
6. Oteseconazole Drug Patents. DrugPatentWatch. Accessed October 26, 2023. https://drugpatentwatch.com/drug/oteseconazole/patents